remain surpris investor arent excit
growth acceler solid execut continu
drive margin expans optim balanc sheet activ
capit deploy result doubl digit ep growth
come high level visibl spite
challeng busi face post-merg encor facil
closur cancel etc furthermor see lead indic
book improv also help valid
thesi expand new busi funnel differenti
offer reson custom ultim low volatil doubl
digit compound rare larg cap think investor
spend time new stori come appreci equiti
respect valuat also find rel multipl
palat tool also point strong gener
despit challeng support continu move higher
thu reiter outperform rate rais pt see share
hold elev gain exhibit today post period mix trade
continu next page
chang earn forecast
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
ltm net new busi bn denot continu momentum book win-rat
capabl continu gain traction sale contribut ahead plan
ex fx bit wors versu street expect
note move account standard januari
mean revenu segment recogn percentag complet basi vs previous
recogn mileston basi
addit servic revenu reimburs expens revenu investig payment treat consist
present one line
segment commerci solut mm solut mm integr engag servic
adjust ebitda mm due natur passthrough ebitda margin compress neg adjust
mm vs prior account
dollar basi includ passthrough sale approxim bn approxim mm commerci solut
 remaind solut
sale growth impact approxim due passthrough sale
mid term expect contribut acquisit
sale growth segment
histor approxim sale recur
 passthrough sale neg impact sale growth vs prior account approxim
due phase clinic trial
believ line sight approxim bn sale
integr engag servic
line expens item mm
adjust dilut ep denot year year growth
assum continu share repurchas activ perhap level saw
bn author remain board increas amount today believ set well beyond
fy guidanc inclus
see lot interest traction market
initi thought could target pipelin
progress think could potenti appli pipelin
time merger expect mm next gen capabl win ahead bn
book site select next gen base trial less day vs benchmark day
timelin site start day vs benchmark day
strength commerci
world busi perform better reorgan integr busi
begin turnaround
encor drag tailwind
stabil
busi lag much year result explor potenti strateg altern
chang go market busi model commerci leader take ownership region level
presenc apac exclud japan see region market growth opportun
bring capabl sale forc
aggress tri build clinic space
strategi build technolog platform across board benefit term platform perform
think strategi littl differ versu other
valuat methodolog valuat methodolog base mix discount cash flow analysi rel valuat
risk disrupt revenu growth inabl replac unforeseen cancel new busi moder
biotech demand due capit market volatil dri invest paus rfp activ follow larg round
pharma industri consolid
laboratori corp america hold
articl articl
time dissemin februari et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
